Apellis Pharmaceuticals Inc
APLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.25B
Close$
$-40.45
198.6% downside
Current Fair Value
198.6% downsideOvervalued by 198.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.25 Billion |
|---|---|
| Enterprise Value | $4.96 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.18 |
| Beta | -0.25 |
| Outstanding Shares | 126,024,000 |
Return
| Return on Equity | 32.12% |
|---|---|
| Return on Assets | 12.31% |
| Return on Invested Capital | 20.21% |
Valuation & Multiples
| P/E Ratio | 38.8 |
|---|---|
| PEG | -32.27 |
| Price to Sales | 8.21 |
| Price to Book Ratio | 13.68 |
| Enterprise Value to Revenue | 6.69 |
| Enterprise Value to EBIT | 30.72 |
| Enterprise Value to Net Income | 37 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$210.47 M
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$208.05 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7182▲ 46.05% |
|---|---|
| Total Calls | 949,600▼ 74.19% |
| Total Puts | 682,032▼ 28.07% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 110.81%▲ 10.52% |
|---|---|
| Total Invested | $5.55B▲ 74.86% |
| Investors Holding | 340▲ 33.00% |
ESG Score
No data
About Apellis Pharmaceuticals Inc
CEO: Cedric Francois